Skip to content

T-2 Toxin Disrupts Alzheimer's-relevant App/Tau Homeostasis via Circadian-p53-Senescence Crosstalk: Evidence from Human Neuroblastoma Cells.

Sep 2026 · Neurotoxicology · Vol 117, pp. 103559 · 0 citations · 32 references
Medicine

TL;DR

It is reported that T‑2 toxin remodels APP and Tau homeostasis, featuring an early decrease in full‑length APP and a delayed, sustained increase in Tau phosphorylation and total Tau, accompanied by dynamic cytokine release.

Abstract

Environmental mycotoxins are pervasive exposures, yet how they perturb Alzheimer's disease (AD)-relevant proteostasis remains unclear. We treated SH-SY5Y cells with low-dose T-2 toxin (6nM) for 24h, and profiled AD-relevant protein changes alongside transcriptomic, circadian, and senescence-related readouts. We report that T‑2 toxin remodels APP and Tau homeostasis, featuring an early decrease in full‑length APP and a delayed, sustained increase in Tau phosphorylation and total Tau, accompanied by dynamic cytokine release. RNA‑seq at 12h revealed a p53‑centered stress response and enrichment of circadian‑related pathways. Cosinor analysis indicated that CLOCK rhythmicity is preserved but reparameterized following T-2 toxin exposure, with a marked phase shift and an elevated mesor. Pharmacological disruption of CLOCK attenuated p53 induction and Tau elevation, whereas inhibition of p53 partially restored APP and reduced Tau changes while reshaping CLOCK abundance and localization, consistent with CLOCK-p53 cross‑regulation. T‑2 toxin also induced a time‑dependent senescence‑like phenotype that was attenuated by CLOCK and/or p53 inhibition. Post‑treatment with senolytic drugs dasatinib and quercetin reduced SA‑β‑gal burden, dampened p53 signaling, and improved the APP/Tau profile. Together, these data link T‑2 toxin exposure to AD‑relevant proteostasis remodeling through a CLOCK-p53-senescence axis and suggest circadian and senescence‑targeting strategies as complementary intervention points.

View source

Similar papers

Review Open access Aug 2026

Investigating the Mechanistic Role of piRNA Dysregulation in Amyloid-beta Toxicity and Tau Pathology in Alzheimer’s Disease Pathophysiology: Implications for Therapeutic Targets

This review synthesizes current knowledge regarding piRNA dysregulation in AD, examining mechanistic links between piRNA loss, transposable element activation, Aβ toxicity, and tau pathology while evaluating therapeutic implications.

S. Taherkhani, Zeynab Sharifiaghdam, Parnian Amani · 0 citations
Review Open access Sep 2026

REV-ERBs as regulators of circadian rhythm, neuroinflammation, and glial lipid homeostasis in Alzheimer’s disease. A narrative review

Alzheimer’s disease (AD) is characterized by progressive cognitive decline, amyloid-β and tau aggregation, and chronic neuroinflammation, processes that are tightly coupled to circadian and metabolic dysfunction. REV-ERBα (NR1D1) and REV-ERBβ (NR1D2) are ligand-dependent nuclear receptors that function as transcription...

Fahmida Shabnam, Meenakshi Singh, Rajesh H. Amin et al. · 0 citations
Review Open access Aug 2026

Retinoic acid-related orphan receptor alpha (RORα) as a candidate multi-pathway target in Alzheimer’s disease: mechanisms and therapeutic prospects

The development of Alzheimer disease (AD) involves a cluster of pathogenic processes, including amyloid-beta (Aβ) deposition, tau-mediated neurodegeneration, chronic neuroinflammation, oxidative stress (OS), metabolic dysregulation, and disruption of circadian rhythms. Nuclear hormone receptor, Retinoic Acid-Related Or...

Shivakanth Chintalapally, Kalpana Rajanala, Arun Upadhyay · 0 citations
Open access Sep 2026

β-Amyloid and Glutathione Dysregulation Cooperatively Drive Lipid Peroxidation and Ferroptosis in Neuron-Like Cells.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) accumulation and oxidative stress, with aging being its greatest risk factor. Age-related glutathione (GSH) depletion may increase neuronal vulnerability to Aβ toxicity, but the underlying mechanisms remain unclear. Her...

Kazi Rafsan Radeen, Cai-Li Hao, Zong-Bo Wei et al. · 0 citations
Open access Oct 2026

Alzheimer’s disease risk gene Wwox controls amyloid pathology through metabolic reprogramming

Findings identify WWOX as a regulator of neuronal metabolic state, linking genetic risk to amyloid pathology via metabolic reprogramming, and highlight WWOX activation as a potential therapeutic strategy in Alzheimer’s disease.

Hannah J. Lucas-Clarke, D. Maddison, L. Amadio et al. · 0 citations
Open access Aug 2026

HSPA8 orchestrates SNARE complex assembly to drive extracellular vesicle-mediated spread of p-tau217 in Alzheimer's disease

Investigating the mechanisms underlying the reduction of p-tau217+ EVs to uncover AD therapeutic targets reveals a role of HSPA8 in regulating the MVB-mediated EV release and tau propagation, and highlights HSPA8 as a promising therapeutic target for modifying AD progression.

Bin Xu, Zhen Guo, Jun Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.